pp-261 Injection
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
GMP approvals
EU GMP
Comments
Indication: Wet age related macular degeneration, Non-proliferative diabetic retinopathy
Clinical stage: Phase 2
Modality: Peptide
Mechanism & Target: Protein target
Route & form: Intravitreal injection
Differentiation: a first-in-class peptide agonist of Protein X (a NF-kB corepressor and to be disclosed under CDA) with differentiated MoA from anti-VEGF therapies.
Manufacturer #39675
A clinical-stage biopharmaceutical company focused on ophthalmology. Developing a biologic therapeutic targeting ophthalmology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None